Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradford Noble

Interventional Pain Medicine Columbia, MO Doctor of Osteopathy

NPI 1316982333 CMS profile 331762

1 S Keene St, Columbia, MO 65201

Open in the dashboard

General payments

$8,409

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradford Noble of Columbia, MO is reported in the CMS Open Payments database as having received $8,409 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $469 8
2024 General $557 26
2023 General $548 18
2022 General $5,015 24
2021 General $854 29
2020 General $600 31
2019 General $365 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradford Noble
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Bradford Noble were reported at $469. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Bradford Noble Interventional Pain Medicine median Middle half National median
2019 $365 $684 $216–$2,079 $163
2020 $600 $382 $122–$1,109 $114
2021 $854 $552 $167–$1,554 $132
2022 $5,015 $605 $187–$1,924 $149
2023 $548 $671 $195–$1,915 $160
2024 $557 $684 $206–$1,837 $164
2025 $469 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vertos Medical, Inc. $4,226 8 payments
  2. Nevro Corp. $2,172 67 payments
  3. Boston Scientific Corporation $1,404 67 payments
  4. MML US, Inc. $224 3 payments
  5. Abbott Laboratories $107 2 payments
  6. Spinal Simplicity, LLC $88 1 payment
  7. Nalu Medical, Inc. $70 1 payment
  8. SPR Therapeutics, Inc $41 1 payment
  9. Relievant Medsystems, Inc. $34 1 payment
  10. Globus Medical, Inc. $23 1 payment
  11. Other $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,409 152 payments
  2. Consulting Fee $4,000 1 payment
Products named General payments · program years 2019–2025
  1. mild Device Kit Orthopedic $4,144 3 payments
  2. Omnia $1,413 28 payments
  3. Senza $759 39 payments
  4. SPECTRA WAVEWRITER Pain Management $614 24 payments
  5. SPECTRA WAVEWRITER Pain Management $225 12 payments
  6. ReActiv8 $224 3 payments
  7. GENERAL - PAIN MANAGEMENT $113 8 payments
  8. PROCLAIM $92 1 payment
  9. HA MINUTEMAN G3-R $88 1 payment
  10. mild Device Kit Orthopedic $82 5 payments
  11. Other $622 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

6,568

Median for Interventional Pain Management: 1,220

Drug cost

$178,627

Median for Interventional Pain Management: $39,344

Branded share of claims

76.8%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,677 $60,736
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 2,322 $55,376
Oxycontin Oxycodone Hcl Brand 15 $27,696
Naloxone Hcl Generic 210 $12,225
Fentanyl Generic 42 $5,278
Tramadol Hcl Generic 426 $4,165
Pregabalin Generic 149 $3,983
Oxycodone Hcl Generic 261 $3,461
Cephalexin Generic 242 $2,648
Gabapentin Generic 131 $1,781

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$357,299

Of which drugs: $1,515

Medicare patients

515

Average age 68

Services billed

4,212

311 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Depression 34%
Diabetes 31%
Ischemic heart disease 24%
COPD 23%
Chronic kidney disease 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 254 1,945 $1,514
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 18 19 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record